ONCOLOGY Staff

Experts in multiple myeloma debated the use of teclistamab through an inpatient or outpatient setting.

Narjust Florez, MD, and Sandip P. Patel, MD, cohosted a X chat centering on treatment options for KRAS G12C non–small cell lung cancer.

The CROWN and ADURA trials were discussed and defended as part of a non–small cell lung cancer Face Off.

Vanderbilt University Medical Center and Winship Cancer Institute at Emory University Face Off on recent data in multiple myeloma and acute lymphoblastic leukemia.

A group of experts discussed the approval process for teclistamab use in patients with multiple myeloma.

An overview of NRG1 fusion–positive tumors was given by experts in the gastrointestinal and lung cancer space in a recent Frontline Forum.

Ghayas C. Issa, MD, gave an all-encompassing review of current treatment options for acute myeloid leukemia and what to expect in the future.

Thomas Hutson, DO, PharmD, meets with his patient Cesar Fuentes to discuss his diagnosis and treatment for renal cell carcinoma.

A Satellite Session, involving members from US Oncology, focused on treatment options for patients with HER2-positive metastatic breast cancer.

During a Morning Rounds discussion, experts in the field of renal cell carcinoma reviewed treatment updates and the effective use of immunotherapy plus TKIs.

Kristen K. Ciombor, MD, MSCI, gives an overview of the current treatment landscape for patients with metastatic colorectal cancer.

Misako Nagasaka, MD, PhD, sheds light on neoadjuvant and adjuvant treatment options for patients with lung cancer.

During the European Society for Medical Oncology 2023, experts discussed updated results in key trials across the lung cancer space.

In a recent Training Academy, experts discussed how to incorporate bispecific antibodies into patients with multiple myeloma.

Experts in the multiple myeloma space met to discuss the treatment and monitoring after bispecific antibodies.

Asher A. Chanan-Khan, MBBS, MD, led a panel discussion surround the use of Bruton tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia.

Karmanos Cancer Institute and Cleveland Clinic gave presentations regarding treatment of multiple myeloma and chronic myeloid leukemia in the latest Face Off.

Sara M. Tolaney, MD, MPH, gives an extensive overview on the current breast cancer landscape and available treatment options.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discussed how to best mitigate adverse effects in patients with non–small cell lung cancer.

UT Southwestern and Mayo Clinic debated over current treatment options in chronic myeloid leukemia and multiple myeloma.

Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.

Tanios S. Bekaii-Saab, MD, gave an overview of colorectal cancer along with current standard of care, and potential treatment options.

John O. Mascarenhas, MD, led a panel discussion on myelofibrosis management including the use of JAK inhibitors and transplantation.

A patient with bladder cancer recounts his diagnosis while Rohit Jain, MD, and Anand B. Shah, PharmD, BCOP, review treatment options and the toxicity associated with them.

Nelson J. Chao, MD, MBA, and his colleagues discussed the use of ruxolitinib as treatment for patients with graft-vs-host disease.

Brian I. Rini, MD, led a panel where he and his colleagues discussed the results of the CLEAR trial and its implications in renal cell carcinoma.

Experts met to debate recently presented trials in the hematologic oncology after the 2023 American Society of Clinical Oncology Annual Meeting.

Jennifer L. Garson, PA-C, gave an overview of follicular lymphoma and how she manages adverse effects in her institution.

Arvind N. Dasari, MD, and Cathy Eng, MD, gave an overview on the use of fruquintinib in colorectal cancer.

Thomas G. Martin, MD, discussed with his colleagues cytokine release syndrome after treatment with teclistamab for patients with multiple myeloma.